Horizon Pharma plc, of Dublin, said wholly owned subsidiaries Horizon Pharma Inc. and Horizon Pharma USA Inc. expect to offer $300 million in senior notes due 2024 and to borrow $375 million in incremental term loans under Horizon's existing senior secured credit facility.